Novartis continues to grow with further core margin expansion and achieves important innovation milestones
Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar
Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio
Subscribe to the latest news and updates from Novartis on email, RSS and more.
Sandoz today has a strong presence on all continents and is well represented in all key generics markets, allowing us to remain close to patients, doctors, healthcare providers and business partners everywhere.